FDA OKs higher dose of Merck’s HIV drug

The Food and Drug Administration on Tuesday approved a new dose of Merck’s HIV drug Isentress.

Advertisement

Patients may now take a 1,200 milligram once-daily dose of Isentress in combination with other antiretroviral treatments. Merck already offers the drug in a 400 milligram twice-daily formulation.

Merck expects the new version of the drug to hit pharmacy shelves within a month.

More articles on supply chain:

Amgen sues FDA over drug exclusivity rights: 5 things to know
Appellate court: Fairvew Health’s medical device telemarketing does not violate robocall rules
Drug execs anticipate Trump’s drug pricing plans: 4 things to know

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.